Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PROSTVAC in Localized Prostate Cancer
NCT02153918Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2014
- Primary completion
- Jul 2017
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rilimogene galvacirepvec in prostate cancer (PCa), sponsored by National Cancer Institute. Started May 2014; status: completed.
02
Drugs
rilimogene galvacirepvec
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02153918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02153918.